MRD as a Surrogate Endpoint for Efficacy Evaluation of New Drugs in Very High Risk ALL: Lessons from Ph ALL FDA Meeting; April 18th, 2012 Stephen P. Hunger, M.D. Chair, COG ALL Committee - Piperazines - Document - PDFSEARCH.IO

First Page	Meta Content
	MRD as a Surrogate Endpoint for Efficacy Evaluation of New Drugs in Very High Risk ALL: Lessons from Ph+ ALL FDA Meeting; April 18th, 2012 Stephen P. Hunger, M.D. Chair, COG ALL Committee Add to Reading List Open Document File Size: 193,54 KB Share Result on Facebook City Philadelphia / / Facility Children’s Hospital / / MedicalCondition Colorado USA Minimal Residual Disease / / MedicalTreatment chemo / chemotherapy / / Organization COG ALL Committee / FDA / Center for Cancer and Blood Disorders / Pediatric Hematology/Oncology/BMT Univ of CO SOM / / Person Pediatric Hematology / Stephen P. Hunger / / Position Cancer Director / Chief / Professor and Ergen Family Chair / M.D. Chair / / Technology chemotherapy / / SocialTag Minimal residual disease Imatinib Chemotherapy Medicine Piperazines Philadelphia chromosome

MRD as a Surrogate Endpoint for Efficacy Evaluation of New Drugs in Very High Risk ALL: Lessons from Ph+ ALL FDA Meeting; April 18th, 2012 Stephen P. Hunger, M.D. Chair, COG ALL CommitteeAdd to Reading List